Clinical Trial Update: Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients [EARLY_Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intravitreal aflibercept 8 mg for resistant diabetic macular edema, retinal vein occlusion, and myopic choroidal neovascularization. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Myopic Choroidal Neovascularization
• Retinal Vein Occlusion

Drugs mentioned

• Aflibercept (Eylea) (aflibercept)

Snippet

Sponsor: Tanta University | Conditions: Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING